Evidence map›Paper›PMID 24240735›Full record

ArticleActa neuropathologica2014

The role of pro-inflammatory S100A9 in Alzheimer's disease amyloid-neuroinflammatory cascade.

Chao Wang, Alexey G Klechikov, Anna L Gharibyan, Sebastian K T S Wärmländer, Jüri Jarvet, Lina Zhao, Xueen Jia, Vinod K Narayana, S K Shankar, Anders Olofsson and 4 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 86 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Can bacteria control the human brain?Communicative & integrative biology · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Chao WangDepartment of Medical Biochemistry and Biophysics, Umeå University, 90187, Umeå, Sweden.
Alexey G Klechikov
Anna L Gharibyan
Sebastian K T S Wärmländer
Jüri Jarvet
Lina Zhao
Xueen Jia
Vinod K Narayana
S K Shankar
Anders Olofsson
Thomas Brännström
Yuguang Mu
Astrid Gräslund
Ludmilla A Morozova-Roche
Umeå University · SENanyang Technological University · SGStockholm University · SENational Institute of Chemical Physics and Biophysics · EENational Institute of Mental Health and Neurosciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pro-inflammatory S100A9 protein is increasingly recognized as an important contributor to inflammation-related neurodegeneration. Here, we provide insights into S100A9 specific mechanisms of action in Alzheimer's disease (AD). Due to its inherent amyloidogenicity S100A9 contributes to amyloid plaque formation together with Aβ. In traumatic brain injury (TBI) S100A9 itself rapidly forms amyloid plaques, which were reactive with oligomer-specific antibodies, but not with Aβ and amyloid fibrillar antibodies. They may serve as precursor-plaques for AD, implicating TBI as an AD risk factor. S100A9 was observed in some hippocampal and cortical neurons in TBI, AD and non-demented aging. In vitro S100A9 forms neurotoxic linear and annular amyloids resembling Aβ protofilaments. S100A9 amyloid cytotoxicity and native S100A9 pro-inflammatory signaling can be mitigated by its co-aggregation with Aβ, which results in a variety of micron-scale amyloid complexes. NMR and molecular docking demonstrated transient interactions between native S100A9 and Aβ. Thus, abundantly present in AD brain pro-inflammatory S100A9, possessing also intrinsic amyloidogenic properties and ability to modulate Aβ aggregation, can serve as a link between the AD amyloid and neuroinflammatory cascades and as a prospective therapeutic target.

Indexed as

AdultAgedAlzheimer DiseaseAmyloid beta-PeptidesBrainBrain InjuriesCalgranulin BCell Line, TumorCell SurvivalCerebral CortexFemaleHumansMaleMiddle AgedModels, MolecularNeuroblastomaAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)Calgranulin BPeptide Fragments

Identifiers

PMID24240735
PMCPMC4148179
OpenAlexW2103491454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.